|
Volumn 31, Issue 32, 2013, Pages 4161-4162
|
Common flaws in pharmacoepidemiologic study design and analysis
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
CANCER RISK;
CARDIOVASCULAR DISEASE;
CHEMOPROPHYLAXIS;
DISEASE COURSE;
DRUG EXPOSURE;
FOLLOW UP;
HEPATITIS C;
HUMAN;
LETTER;
LIVER CELL CARCINOMA;
PHARMACOEPIDEMIOLOGY;
PRIORITY JOURNAL;
PROGNOSIS;
RISK REDUCTION;
TREATMENT DURATION;
FEMALE;
LIVER TUMOR;
MALE;
NOTE;
CARCINOMA, HEPATOCELLULAR;
COMPLICATION;
LIVER NEOPLASMS;
CARCINOMA, HEPATOCELLULAR;
FEMALE;
HEPATITIS C;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
LIVER NEOPLASMS;
MALE;
|
EID: 84891665666
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2013.51.5593 Document Type: Letter |
Times cited : (8)
|
References (6)
|